FIELD: medicine; pharmaceuticals.
SUBSTANCE: present invention describes a composition, methods and a kit for treating inflammatory bowel disease (IBD), such as Crohn's disease and ulcerative colitis in a mammal in need of such treatment. Described method involves the use of a combined therapy comprising a therapeutically effective amount of chemokine receptor 9 (CCR9) inhibitor to an IBD patient, and a therapeutically effective amount of an antibody blocking α4β7-integrin, which is vedolizumab or antibodies directed against TNFα. Disclosed pharmaceutical composition and kit contain a CCR9 inhibitor and the above blocking antibody α4β7 integrin. Present CCR9 inhibitor is a compound having the following structural formula or a pharmaceutically acceptable salt thereof.
EFFECT: invention provides treatment of inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.
11 cl, 12 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMBINATION THERAPY WITH C-C CHEMOKINE RECEPTOR 9 (CCR9) INHIBITORS AND α4β7-INTEGRIN BLOCKING ANTIBODIES | 2015 |
|
RU2823984C2 |
| METHOD FOR TREATMENT OF PEDIATRIC DISORDERS/DISEASES | 2018 |
|
RU2778567C2 |
| COMBINATION THERAPY USING CC CHEMOKINE RECEPTOR 4 (CCR4) ANTAGONISTS AND ONE OR MORE CHECKPOINT INHIBITORS | 2019 |
|
RU2810717C2 |
| SOLUBLE C5aR ANTAGONISTS | 2017 |
|
RU2748260C2 |
| METHODS FOR MONITORING RESPONSIVENESS TO ANTI-SMAD7 THERAPY | 2012 |
|
RU2678450C2 |
| COMBINATION THERAPY WITH A CHEMOKINE RECEPTOR 2 (CCR2) ANTAGONIST AND A PD-1/PD-L1 INHIBITOR | 2018 |
|
RU2796863C2 |
| REDUCTION OF TUMOR MASS BY INJECTING CCR1 ANTAGONISTS IN COMBINATION WITH PD-1 INHIBITORS OR PD-L1 INHIBITORS | 2017 |
|
RU2745195C2 |
| 2-OXINDOLE COMPOUNDS | 2017 |
|
RU2743747C2 |
| METHOD OF IMPROVING CONDITION OF DIGESTIVE SYSTEM | 2020 |
|
RU2815487C2 |
| HOMODETIC CYCLIC PEPTIDES SPECIFICALLY ACTING ON α4β7 INTEGRIN | 2018 |
|
RU2773443C2 |
